Global Viral Conjunctivitis Drugs Market 2016-2020
About Viral Conjunctivitis Drugs
Viral conjunctivitis, or pink eye, is a type of infectious conjunctivitis that is commonly caused by an adenovirus. Herpes simplex virus (HSV), picornavirus (enterovirus 70, Coxsackie A24), varicella-zoster virus, poxvirus (molluscum contagiosum and vaccinia), and human immunodeficiency virus (HIV) are some of the other viruses that are responsible for the infection. Discomfort through watery discharge is the main symptom of this highly contagious condition. It is often associated with keratoconjunctivitis, which results in slightly blurred vision. No specific treatment option is available for the infection, which heals by itself in 2-3 weeks. Antibiotics and anti-inflammatory drugs are used only if the condition persists. In certain instances, when the infection is serious or persists for weeks, topical antiviral drugs are used. Corneal lesions persist for months even after the condition heals.
Technavio’s analysts forecast the global viral conjunctivitis drugs market to grow at a CAGR of 2.41% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global viral conjunctivitis drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of viral conjunctivitis.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Viral Conjunctivitis Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Viral Conjunctivitis Drugs Market: Akorn, Alcon, Allergan, and Bausch & Lomb.
Other Prominent Vendors in the market are: Adenovir Pharma, Marinomed Biotechnologie, Mediolanum Laboratoires, NanoViricides, Nicox, Novartis, Panoptes Pharma, Rapid Pathogen Screening, Shire, Starpharma, and Valeant Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “The unavailability of approved drugs for the treatment of diseases results in increased use of off-label drugs. These drugs are available at lower prices. Topical NSAIDs and lubricants are used as off-label treatments for ophthalmic indications. Though the safety profiles of these drugs are not determined by the US Food and Drug Administration (FDA), they are available in the market for a number of indications.”
According to the report, awareness programs and campaigns by organizations in public and private sectors to help individuals understand how to treat and control the spread of the viral conjunctivitis infection will result in more people opting for treatment.
Further, the report states that the diagnosis rates of viral conjunctivitis are observed to be low, as most people prefer to allow the condition to heal on its own. Misdiagnosis also leads to the low diagnosis rate.
Akorn, Alcon, Allergan, Bausch & Lomb, Adenovir Pharma, Marinomed Biotechnologie, Mediolanum Laboratoires, NanoViricides, Nicox, Novartis, Panoptes Pharma, Rapid Pathogen Screening, Shire, Starpharma, Valeant Pharmaceuticals.